BIRAC-New

Oraxion Therapeutics, a spin-off from BIRAC supported Aten Porus Lifesciences has entered into an "Option to License" agreement for US $125 Million with a US-based biopharma company to licence its drug ORX-301 for the treatment of rare diseases

  • Home
  • Oraxion Therapeutics, a spin-off from BIRAC supported Aten Porus Lifesciences has entered into an "Option to License" agreement for US $125 Million with a US-based biopharma company to licence its drug ORX-301 for the treatment of rare diseases

https://www.biovoicenews.com/indian-startup-develops-drug-for-key-orphan-diseases-partners-us-firm/

http://www.prweb.com/releases/2018/02/prweb15153457.htm

http://www.businessworld.in/article/Oraxion-Executes-Exclusive-Option-to-License-ORX-301/05-02-2018-139541/

 

Annual Reports
Compliance
RTI
DBT-BIRAC MOU
Birac News
Tenders   gif
Vacancy  gif
What's New
Loan Non-repayment
Caution
Supported projects  
TRL   gif
Feedback  |  Contact Us

This is the official Website of Biotechnology Industry Research Assistance Council (BIRAC) , a Public Sector Enterprise, set up by Department of Biotechnology (DBT), Government of India © 2024

Last Updated: 07 November, 2024

g20
mygov
indiagov